Top Markets
Coin of the day
Guerbet S.A. Guerbet S.A.

Guerbet S.A.

GBT
Rangering i aksjer #20963
Guerbet SA is dedicated to the development and commercialization of a broad... Guerbet SA is dedicated to the development and commercialization of a broad spectrum of contrast media, advanced delivery systems, medical devices, and related solutions for diagnostic imaging. Their extensive product lineup features iodinated contrast agents such as Optiray and Xenetix, both non-ionic monomeric; Telebrix Gastro, a meglumine ioxitalamate solution; and Conray, an iothalamate meglumine injection. They also offer Micropaque/Microtrast, an integrated diagnostic imaging solution. For MRI applications, the company provides gadoteric acid-based contrast agents like Dotarem (gadoterate meglumine) and Artirem. Complementing these are essential delivery systems and consumables, including prefilled syringes, injectors, and accessories designed for use in MRI, CT, and Cath Lab settings. Guerbet also delivers innovative digital health solutions such as Contrast&Care for injection management, Dose&Care for X-ray dose management, and icobrain, a cloud-based AI platform that quantifies disease-specific brain structures from MR and CT scans for acute and chronic neurological conditions. Additionally, they offer OptiProtect services. In the realm of interventional radiology, the company provides products like Lipiodol (ethyl esters of iodinated fatty acids of poppyseed oil), Vectorio (a mixing and injection system for conventional trans-arterial chemoembolization), Patent Blue V (a blue dye), Axessio (a peripheral micro guidewire), and microcatheters such as SeQure and DraKon. Furthermore, their offerings include Hydra Vision, a digital imaging system tailored for urological, gastroenterological, and gynecological treatment, planning, and diagnostic procedures, alongside various urology accessories and consumables. Established in 1926, Guerbet's headquarters are situated in Villepinte, France.
Aksjekurs
$9.37
Sist synkronisert: 2026-08-21
Markedsverdi
$118.21M
Endring (1 dag)
1.94%
Endring (1 år)
-64.47%
Land
FR
Handel Guerbet S.A. (GBT)

Kategori

P/E-forhold for Guerbet S.A. (GBT)
P/E-forhold per 2026 TTM: 0
Ifølge Guerbet S.A. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Guerbet S.A. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.